Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
dac n-055 (1 trial)
sodium chloride (1 trial)
Leishmaniasis (Phase 3)
Leishmaniasis, Cutaneous (Phase 3)
Trials (1 total)
Trial APIs (2 total)